article thumbnail

Medtech: BrainTale Gathers €4.5 Million to Accelerate the Development of Its Solution for Diagnosis, Monitoring and Prediction of Neurological Disorders

Digital Health Global

Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drug developers and physicians – neurologists, neuroradiologists and intensivists.

article thumbnail

6 challenges healthtech can help us tackle – Pt.2

Digital Health Global

Drug development The traditional drug discovery process is characterized by its protracted timeline, high costs, and significant attrition rates among drug candidates. There are three main advantages to the use of AI in drug development: width of research, speed of execution, low costs. 2021 [6] Regina M.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Playing the Waiting Game While Living with a Rare Disease

Society for Participatory Medicine

I enrolled in the Jain Foundation’s natural history study in 2012, and it tracked me for four years, providing data on my disease progression and biomarkers that are essential if companies are going to become interested in drug development. See if there is a natural history or observational study.

article thumbnail

FDA’s rejection of SGLT for T1D

Insulin Nation

Ever since the first SGLT2 inhibitor (dapagliflozin) was approved by the EU in 2011 and the USA in 2014, it and another nine gliflozin drugs developed since then have been considered for (off-label) use in Type-1 diabetes, as well as in Type-2 diabetes for which they were first approved.